Skip to content
Peptide research

Syn-Ake

Also known as Dipeptide Diaminobutyroyl Benzylamide Diacetate
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

What it is

A synthetic tripeptide mimicking waglerin-1 from Temple Viper venom, used topically to relax facial muscles and soften expression lines as a Botox alternative. Evidence remains limited, with laboratory findings and small industry-affiliated human studies. The main risk is poor skin penetration that may keep it from reaching muscle, plus inconsistent quality. It is a cosmetic ingredient, not an approved drug, sold in skincare products and as unregulated products online.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Reduction of expression wrinkles and crow's feet

    Speculative

    A 2026 controlled split-face pilot included five Syn-Ake participants; larger replication is needed.

  • Non-invasive muscle relaxation (topical Botox alternative)

    Speculative

    Receptor inhibition has laboratory support. Human topical studies exist, but do not directly establish facial-muscle relaxation.

  • Antioxidant activity and ROS scavenging

    Speculative

    Based on a single in vitro chemical assay, not cellular or human testing.

Evidence limits

Evidence Level
Moderate

The clinical evidence base for Syn-Ake is limited to manufacturer-sponsored efficacy data and supportive mechanistic research. The primary efficacy claim — up to 52% wrinkle reduction after 28 days — comes from Pentapharm's in-house in vivo study using 4% Syn-Ake cream, which measured skin surface parameters objectively (profilometry) but was not published in a peer-reviewed journal or independently replicated. The underlying mechanism (nAChR antagonism causing muscle relaxation) is well-supported by independent academic research on waglerin-1 peptides (Molles et al. 1999, McArdle et al. 2002). A 2024 study (Bang et al., PMID 39063099) independently confirmed Syn-Ake's nAChR inhibitory activity but primarily as a comparison control for a novel peptide. The 2024 review by Nguyen et al. in Cosmetics noted only six clinical validations total for Botox-like peptides (including Syn-Ake, Argireline, and SNAP-8). Major evidence gaps include: (1) no independent RCTs, (2) no long-term efficacy or safety data, (3) no head-to-head comparison with Botox or other neuromuscular peptides in peer-reviewed trials, and (4) the well-documented challenge of poor peptide permeability through the stratum corneum, which may limit in vivo efficacy compared to in vitro results.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Limited independent clinical validation

    High
  • Poor skin penetration may limit efficacy

    Moderate
  • Product quality variability

    Moderate
  • Skin irritation and allergic reaction

    Low
  • Pregnancy and lactation safety unknown

    Low
  • Acute dermal toxicity at high concentrations

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.